vs
Side-by-side financial comparison of Commercial Bancgroup, Inc. (CBK) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $16.1M, roughly 1.4× Journey Medical Corp). Commercial Bancgroup, Inc. runs the higher net margin — 41.3% vs -7.8%, a 49.1% gap on every dollar of revenue.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
CBK vs DERM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $16.1M |
| Net Profit | $9.5M | $-1.2M |
| Gross Margin | — | — |
| Operating Margin | — | -2.8% |
| Net Margin | 41.3% | -7.8% |
| Revenue YoY | — | 27.3% |
| Net Profit YoY | 9.7% | -182.0% |
| EPS (diluted) | $0.69 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | $16.1M | ||
| Q3 25 | $22.8M | $17.0M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $12.6M | ||
| Q3 24 | — | $14.6M | ||
| Q2 24 | — | $14.9M |
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | $-1.2M | ||
| Q3 25 | $9.5M | $-2.3M | ||
| Q2 25 | — | $-3.8M | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-3.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | -2.8% | ||
| Q3 25 | 53.8% | -9.0% | ||
| Q2 25 | — | -19.2% | ||
| Q1 25 | — | -25.3% | ||
| Q4 24 | — | 17.7% | ||
| Q3 24 | — | -19.8% | ||
| Q2 24 | — | -19.7% |
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | -7.8% | ||
| Q3 25 | 41.4% | -13.6% | ||
| Q2 25 | — | -25.3% | ||
| Q1 25 | — | -31.0% | ||
| Q4 24 | — | 12.1% | ||
| Q3 24 | — | -16.3% | ||
| Q2 24 | — | -22.6% |
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | $-0.04 | ||
| Q3 25 | $0.77 | $-0.09 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $-0.12 | ||
| Q2 24 | — | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $24.1M |
| Total DebtLower is stronger | $118.2M | $25.3M |
| Stockholders' EquityBook value | — | $31.9M |
| Total Assets | $2.3B | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $24.1M | ||
| Q3 25 | $154.8M | $24.9M | ||
| Q2 25 | — | $20.3M | ||
| Q1 25 | — | $21.1M | ||
| Q4 24 | — | $20.3M | ||
| Q3 24 | — | $22.5M | ||
| Q2 24 | — | $23.9M |
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | $25.3M | ||
| Q3 25 | $100.1M | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $31.9M | ||
| Q3 25 | $245.2M | $25.9M | ||
| Q2 25 | — | $19.2M | ||
| Q1 25 | — | $21.5M | ||
| Q4 24 | — | $20.1M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $11.3M |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $94.6M | ||
| Q3 25 | $2.2B | $85.2M | ||
| Q2 25 | — | $81.2M | ||
| Q1 25 | — | $85.0M | ||
| Q4 24 | — | $80.2M | ||
| Q3 24 | — | $64.0M | ||
| Q2 24 | — | $65.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.79× | ||
| Q3 25 | 0.41× | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-6.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-6.3M | ||
| Q3 25 | $28.0M | $-2.4M | ||
| Q2 25 | — | $-942.0K | ||
| Q1 25 | — | $-2.8M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | — | $-5.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $26.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 115.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
